This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatology  • Dermatologic Disorders  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Hematology/ Hematologic Malignancies  • Coagulation Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Andrew H. Kalajian, MD; Klark B. Turpen, MD; Kristin O. Donovan, MD; Janine C. Malone, MD; Jeffrey P. Callen, MD

Arch Dermatol. 2007;143(10):1314-1317.

Background  Cutaneous microvascular occlusion syndromes (MOS) present with noninflammatory retiform purpura with variable outcomes that are dependent on the severity, duration, and specific underlying cause. Transient cases are often associated with few sequelae, while severe forms such as symmetrical peripheral gangrene may be associated with amputation and death.

Observations  A middle-aged man developed MOS after exposure to phenylephrine hydrochloride and experienced complete resolution when treatment with the vasopressor was discontinued. Further evaluation detected a previously subclinical heterozygous factor V Leiden mutation.

Conclusions  We propose that phenylephrine-mediated vasoconstriction superimposed on an underlying thrombotic predisposition precipitated the transient MOS. The role of vasopressors in the development of cutaneous MOS is well documented in the critical care literature; however, it is underrepresented in the dermatologic literature, and, to our knowledge, there are no reports of phenylephrine use inducing MOS. We hope to raise awareness of the potential role of vasopressor medications in causing MOS.

Author Affiliations: Division of Dermatology, Department of Medicine, University of Louisville, Louisville, Kentucky.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?